[EN] COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF<br/>[FR] COMPOSITION POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES MÉTABOLIQUES, ET SON PROCÉDÉ DE PRÉPARATION
申请人:UNIV KAOHSIUNG MEDICAL
公开号:WO2013022951A1
公开(公告)日:2013-02-14
Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.
COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF
申请人:Wu Yang-Chang
公开号:US20140350304A1
公开(公告)日:2014-11-27
Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.
Chalcones bearing electron donating or electron withdrawing substitutions were prepared and their glucose uptake activity was evaluated. Chalcone derivatives were synthesized in one step protocol with high purity and yield. Chalcones with chloro, bromo, iodo and hydroxy substitutions at position 2 on A-ring exhibited the highest activity with glucose medium concentration (210 to 236 mg/dl) compared to pioglitazone and rosiglitazone (230 and 263 mg/dl, respectively). Also chalcones with iodo substitution at position 3 on A-ring were comparably active (<= 238 mg/dl). The structure-activity relationship of the tested chalcones was studied and the findings were supported statistically (C) 2012 Elsevier Ltd. All rights reserved.
US9085520B2
申请人:——
公开号:US9085520B2
公开(公告)日:2015-07-21
Impact of mono- and disubstitution on the colorimetric dynamic covalent switching chalcone/flavanone scaffold
作者:Brian M. Muller、Jesse Mai、Reid A. Yocum、Marc J. Adler
DOI:10.1039/c4ob00398e
日期:——
The impact of substitution on a novel colorimetric dynamic covalent switching scaffold was investigated using UV/Vis and NMR spectroscopy.